Results 101 to 110 of about 830,895 (193)

Histone Deacetylase Inhibitors (HDACis) as Latency-Reversing Agents in HIV Cure Strategies: Chemistry, Selectivity, and Clinical Perspective. [PDF]

Viruses
Almolhim H.
europepmc   +1 more source

Design and Synthesis of Bicyclic Tetrapeptides for Cap Group Optimization toward Histone Deacetylase Inhibitors

Chapter 1. Histone Deacetylase Inhibitors||Chapter 2. Molecular Design of Bicyclic Tetrapeptide Histone Deacetylase Inhibitors by Changing Aliphatic Loop Length||Chapter 3.
Nurul, Md Islam
core  

Adverse drug reaction profiles of histone deacetylase inhibitors. [PDF]

Sci Rep
Begum R, Parsons JL, Jones AM.
europepmc   +1 more source

Molecular Design, Synthesis and Simulation of Histone Deacetylase Inhibitors

1 Histone Deacetylase and Histone Deacetylase Inhibitors||2 Molecular Simulation of Interactions between HDAC and Apicidin, Analogues||3 Synthesis of Non-natural Amino Acid||4 Molecular Design of Cyclic Tetrapeptide HDAC Inhibitors by Replacement of Aib ...
Li, Xiao Hui
core  

Design, synthesis, and biological evaluation of phenylisoxazole-based histone deacetylase inhibitors. [PDF]

PLoS One
Qin X, Han M, Hu P, Que H, Shao Z, Yan D.   +5 more
europepmc   +1 more source

Hypophosphatemia as a Potential Class Effect of Histone Deacetylase Inhibitors: Evidence from Disproportionality Analysis and Mendelian Randomization Analysis of Drug Targets. [PDF]

Pharmaceuticals (Basel)
Zhao R, Zhang B, Han M, Lv M, Sun J, Zhou X.   +5 more
europepmc   +1 more source

Recent Insights into the Creation of Histone Deacetylase Inhibitors for the Treatment of Human Diseases. [PDF]

Int J Mol Sci
Yudaev P, Aleksandrova Y, Neganova M.
europepmc   +1 more source

Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells. [PDF]

Sci Rep
Tehrani GA, Kubick RN, Zarodniuk M, Datta M.   +3 more
europepmc   +1 more source

Microbial short chain fatty acids: Effective histone deacetylase inhibitors in immune regulation (Review). [PDF]

Int J Mol Med
Wang J, Zhao Q, Zhang S, Liu J, Fan X, Han B, Hou Y, Ai X.   +7 more
europepmc   +1 more source

Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. [PDF]

World J Clin Oncol
Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF.   +5 more
europepmc   +1 more source